ArticleNucleic acid therapeutics2019
RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise.
Article in Nucleic acid therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Albumin-binding dendritic siRNA improves delivery and efficacy to solid tumors in a melanoma model.Molecular therapy. Nucleic acids · 2025Article
- Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Carbon-based Nanomaterials for Delivery of Small RNA Molecules: A Focus on Potential Cancer Treatment Applications.Pharmaceutical nanotechnology · 2022Review
- Enzymatic ligation of an antibody and arginine 9 peptide for efficient and cell-specific siRNA delivery.Scientific reports · 2021Article
- Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment.Pharmaceutics · 2021Review
- Advancing peptide siRNA-carrier designs through L/D-amino acid stereochemical modifications to enhance gene silencing.Molecular therapy. Nucleic acids · 2021Article
- Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review.ACS pharmacology & translational science · 2021Review
- Breast Milk: A Source of Functional Compounds with Potential Application in Nutrition and Therapy.Nutrients · 2021Review
- RNA-based therapies: A cog in the wheel of lung cancer defense.Molecular cancer · 2021Review
- Long non-coding RNA-based glycolysis-targeted cancer therapy: feasibility, progression and limitations.Molecular biology reports · 2021Review
- The Astrogenic Balance in the Aging Brain.Current neuropharmacology · 2021Review
- Cancer biology functional genomics: From small RNAs to big dreams.Molecular carcinogenesis · 2020Article
- More than Nutrition: Therapeutic Potential of Breast Milk-Derived Exosomes in Cancer.International journal of molecular sciences · 2020Review
- Long non-coding RNA LINC00467 drives hepatocellular carcinoma progression via inhibiting NR4A3.Journal of cellular and molecular medicine · 2020Article
- Expression pattern of placenta specific 8 and keratin 20 in different types of gastrointestinal cancer.Molecular medicine reports · 2020Article
- Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Localized RNA interference therapy to eliminate residual lung cancer after incomplete microwave ablation.Thoracic cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Nucleic acid-based therapeutics like synthetic small interfering RNAs have been exploited to modulate gene function, taking advantage of RNA interference (RNAi), an evolutionally conserved biological process. Recently, the world's first RNAi drug was approved for a rare genetic disorder in the liver. However, there are significant challenges that need to be resolved before RNAi can be translated in other genetic diseases like cancer. Current drug delivery platforms for therapeutic silencing RNAs are tailored to hepatic targets. RNAi therapies for nonhepatic conditions are still at early clinical phases. In this study, we discuss the critical design considerations in anticancer RNAi drug development, insights gained from initial clinical trials, and new strategies that are entering clinical development, shaping the future of RNAi in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.